MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Claudio Pulito und 27 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, MicroRNAs, Drug Resistance, Neoplasm, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Ministry of Health, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
AIMS: Head and neck squamous cell carcinomas (HNSCCs) frequently harbor alterations in the PI3K signalling axis and, particularly, in the PIK3CA gene. The promising rationale of using PI3K inhibitors for the treatment of HNSCC has, however, clashed with the spontaneous development of resistance over time. METHODS: To identify valuable targets for overcoming acquired resistance to PI3Kα inhibitors in HNSCC, we performed microRNA profiling on a cohort of HNSCC PDXs that were treated with alpelisib, including both responsive and resistant tumors. Using CRISPR/Cas9, siRNA, and PTEN-/- isogenic and alpelisib-resistant cell models, we examined the role of PTEN in resistance acquisition. Phospho-proteomic analysis identified PTEN-dependent phosphorylation events, while PI3Kα inhibitor-resistant organoids were used to assess PLK1 inhibitor efficacy. RESULTS: We identified microRNAs altered in resistant PDXs, including members of the miR-17-92 cluster. Mechanistically, we observed that the hyperactive c-Myc was recruited to MIR17HG regulatory regions in alpelisib-resistant cells, sustaining miR-17-5p, miR-19b-3p, and miR-20a-5p expression, which downregulated PTEN. PTEN knockout or depletion conferred alpelisib resistance in HNSCC cells. We identified PTEN-dependent phosphorylation events, such as p-PLK1-T210, involved in resistance. Interestingly, pharmacological inhibition of PLK1 strongly reduced the viability of PI3Kα-resistant organoids derived from HNSCC PDXs and cell line models. CONCLUSION: Overall, this study unveils a novel, microRNA-driven, non-genetic mechanism contributing to acquired resistance to PI3Kα inhibitors in HNSCC. Indeed, linking hyperactive c-Myc to sustain miR-17-92 expression and consequent PTEN downregulation, we also propose that targeting PTEN-dependent downstream effectors, such as PLK1, may offer a powerful therapeutic strategy for resistant HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.
- Microbiology and Virology Unit, San Gallicano Dermatological Institute IRCSS, Rome 00144, Italy.
- UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.
- Department of Radiooncology and Radiotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
- Department of Otorhinolaryngology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.
- Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
- Ministry of Health
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Pulito, C., Vaccarella, S., Palcau, A. C., Ganci, F., Brandi, R., Frascolla, C., Sacconi, A., Canu, V., Benedetti, A., De Pascale, V., Donzelli, S., Fisch, A. S., Manciocco, V., Covello, R., Pimpinelli, F., Morrone, A., Fazi, F., Pellini, R., Muti, P., …, & Blandino, G. (2025). MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101251
Vancouver
Pulito C, Vaccarella S, Palcau AC, Ganci F, Brandi R, Frascolla C, et al. MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101251
BibTeX
@article{Pulito2025,
author = {Pulito, Claudio and Vaccarella, Sebastiano and Palcau, Alina Catalina and Ganci, Federica and Brandi, Renata and Frascolla, Carlotta and Sacconi, Andrea and Canu, Valeria and Benedetti, Anna and De Pascale, Valentina and Donzelli, Sara and Fisch, Anne-Sophie and Manciocco, Valentina and Covello, Renato and Pimpinelli, Fulvia and Morrone, Aldo and Fazi, Francesco and Pellini, Raul and Muti, Paola and Meens, Jalna and Karamboulas, Christina and Nichols, Anthony C and Strano, Sabrina and Klinghammer, Konrad and Tinhofer, Ingeborg and Ailles, Laurie and Fontemaggi, Giulia and Blandino, Giovanni},
title = {MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101251}
}
EUVIMED